Sign in
Active, not recruitingPhase 2

Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure

Key facts

Who runs it
Northwestern University
Where
Chicago, United StatesSee the site
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
60 people enrolled
Started
1 Jan 2021
Ended
1 Jun 2025
Type of study
Interventional, 2 groups
Treatments tested
  • Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet
  • Naproxen 500 Mg
  • Opioids
Record updated
27 November 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (27)Hide the full registry criteria

Who can take part

  • History of low back pain for a minimum of 6 months daily (prior to screening), meeting the Quebec Task Force Classification System symptom categories I-III
  • Male or female, age equal or greater than 18 years, with no racial/ethnic restrictions
  • Must be able to read and speak English and be willing to read and understand instructions as well as questionnaires
  • Must be in generally stable health
  • Must sign an informed consent document after a complete explanation of the study documenting that they understand the purpose of the study, procedures to be undertaken, possible benefits and potential risks, and are willing to participate
  • Must have, on average ≥ 4/10 units of pain intensity over the course of a 1-4 week period prior to the brain scanning visit
  • Must be willing to complete daily smartphone/computer eDiary ratings
  • Must be on regular opioid therapy or for at least 3 months prior to randomization which will be up to the clinical investigator's decision
  • Must be on a short acting opioid therapy (anticipated duration of action < 6 hours)

Who cannot take part

  • Use of therapeutic doses of antidepressant medications at unstable doses (i.e., tricyclic depressants, SSRIs, SNRIs; low doses used for sleep may be allowed)
  • Intra-axial implants (e.g. spinal cord stimulators or pumps)
  • All exclusion criteria for MR safety: any metallic implants, brain or skull abnormalities, tattoos on large body parts, and claustrophobia
  • Use of a patch or long acting opioid therapy (e.g. anticipated duration of action > 6 hours)
  • Other comorbid chronic pain or neurological conditions
  • Significant other unstable medical disease such as diabetes, congestive heart failure, coronary or peripheral vascular disease, chronic obstructive lung disease, or malignancy
  • Uncontrolled hypertension
  • Any medical condition that in the investigator's judgment may prevent the individual from completing the study or put the individual at undue risk
  • An established diagnosis of diabetes (type 1 or type 2)
  • History of an allergic reaction to naproxen or any NSAID
  • History of any untoward reaction to carbidopa/levodopa
  • Renal insufficiency;(correlated creatinine clearance < 40mL/min or serum creatinine ≥2)
  • Pregnancy, or inability to use an effective form of contraception in women of child-bearing age
  • Low back pain associated with any systemic signs or symptoms, e.g., fever, chills
  • Daily use of high doses of opioids,, as defined as > 50mg morphine equivalent/day
  • In the judgment of the investigator, unable or unwilling to follow protocol and instructions
  • Evidence of poor treatment compliance, in the judgment of the investigator
  • Lactose intolerance

Where in United States

  • Northwestern University Feinberg School of MedicineChicago, United States

About the trial

What the trial wants to find out

This study is designed to track brain functional changes in individuals with i) chronic back pain + opioid use (CBP+O) and individuals with ii) chronic back pain + opioid misuse disorder (CBP+mOUD) following a brief drug delay and re-exposure manipulation. Re-exposure could be placebo, the participant's own opioid dose, or a dopaminergic treatment (DA+NSAID). The participants will be also evaluated for changes in cognition, emotion, and motor abilities with opioid delay and re-exposure to placebo, opioid, or DA+NSAID.

The 2 groups in the trial

  • Chronic Back Pain with Opioid UseTreatment being tested

    Subjects of this arms will be on a previously prescribed, short term acting opioid. Previous to each of the three imaging visits, subjects will be instructed to withhold from taking their regular morning opioid dose. Subjects will be randomized into a group that determines the sequence of which they will receive the study drugs. The three sequences are as follows: 1. treatment dose #1: 25mg carbidopa/ 100mg levodopa + 500mg naproxen, treatment dose #2: subjects prescribed, short acting opioid; 2. treatment dose #1: placebo, treatment dose #2: subjects prescribed, short acting opioid; or 3. treatment #1: subjects prescribed, short acting opioid, treatment dose #2: placebo.

    Treatment: Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet, Naproxen 500 Mg, and Opioids

  • Chronic Back Pain with Opioid Misuse DisorderTreatment being tested

    Subjects of this arms will be on a previously prescribed, short term acting opioid. Previous to each of the three imaging visits, subjects will be instructed to withhold from taking their regular morning opioid dose. Subjects will be randomized into a group that determines the sequence of which they will receive the study drugs. The three sequences are as follows: 1. treatment dose #1: 25mg carbidopa/ 100mg levodopa + 500mg naproxen, treatment dose #2: subjects prescribed, short acting opioid; 2. treatment dose #1: placebo, treatment dose #2: subjects prescribed, short acting opioid; or 3. treatment #1: subjects prescribed, short acting opioid, treatment dose #2: placebo.

    Treatment: Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet, Naproxen 500 Mg, and Opioids

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
27 November 2024